What is HC Wainwright’s Estimate for BEAM FY2025 Earnings?

Beam Therapeutics Inc. (NASDAQ:BEAM) – Analysts at HC Wainwright decreased their FY2025 EPS estimates for Beam Therapeutics in a research note issued to investors on Wednesday, November 5th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($4.22) per share for the year, down from their previous forecast of ($3.78). HC Wainwright has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q4 2025 earnings at ($0.90) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.87) EPS, FY2026 earnings at ($3.53) EPS, FY2027 earnings at ($3.24) EPS, FY2028 earnings at ($2.11) EPS and FY2029 earnings at ($1.66) EPS.

BEAM has been the subject of several other reports. Cantor Fitzgerald upgraded Beam Therapeutics to a “strong-buy” rating in a report on Monday, July 21st. Jefferies Financial Group started coverage on shares of Beam Therapeutics in a research report on Thursday, October 9th. They issued a “buy” rating and a $41.00 price target on the stock. Wall Street Zen downgraded shares of Beam Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beam Therapeutics in a research note on Wednesday, October 8th. Finally, Barclays cut their target price on shares of Beam Therapeutics from $25.00 to $21.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $46.55.

Beam Therapeutics Stock Performance

BEAM opened at $22.21 on Friday. The company has a market cap of $2.25 billion, a PE ratio of -5.01 and a beta of 2.40. The stock has a 50-day moving average of $23.98 and a 200-day moving average of $20.25. Beam Therapeutics has a 52-week low of $13.52 and a 52-week high of $35.25.

Beam Therapeutics (NASDAQ:BEAM) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.12). The business had revenue of $9.70 million during the quarter, compared to analyst estimates of $12.83 million. Beam Therapeutics had a negative net margin of 744.41% and a negative return on equity of 42.86%. The firm’s revenue for the quarter was down 32.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.17) EPS.

Hedge Funds Weigh In On Beam Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Amalgamated Bank raised its stake in Beam Therapeutics by 20.4% during the 1st quarter. Amalgamated Bank now owns 3,153 shares of the company’s stock valued at $62,000 after purchasing an additional 534 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Beam Therapeutics by 2.2% during the 3rd quarter. Arizona State Retirement System now owns 26,771 shares of the company’s stock worth $650,000 after purchasing an additional 580 shares during the period. Martingale Asset Management L P raised its position in shares of Beam Therapeutics by 5.2% during the first quarter. Martingale Asset Management L P now owns 12,038 shares of the company’s stock valued at $235,000 after buying an additional 600 shares during the last quarter. Profund Advisors LLC raised its position in shares of Beam Therapeutics by 3.0% during the second quarter. Profund Advisors LLC now owns 26,183 shares of the company’s stock valued at $445,000 after buying an additional 758 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Beam Therapeutics by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 10,492 shares of the company’s stock valued at $205,000 after buying an additional 879 shares during the period. Institutional investors own 99.68% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.